Top Private Equity Firms in Israel
Israel punches well above its weight in private equity activity. Global PE and VC investment in the country surpassed $5 billion in the first eight months of 2025 alone, according to S&P Global Market Intelligence, with aggregate deal value climbing year over year and PE-specific transactions nearing $3 billion in recent periods. The market is shaped by a few dominant generalist platforms, a cluster of technology-focused growth investors, and several specialists that have carved out defensible niches in healthcare, sports technology, and mezzanine financing.
A filter table can tell you who's out there. It can't tell you why a founder should pick one generalist platform over another, or when a niche specialist actually beats a bigger name. That's what the profiles below are for: what makes each firm structurally distinct, how they stack up against each other, and what that means for where a founder or investor should focus first.
1. FIMI Opportunity Funds
Seven funds, $4.3 billion in aggregate capital commitments, and a most recent raise of $1.75 billion that stood as the largest single fundraise in Israeli private equity history. Those numbers alone put FIMI Opportunity Funds in a different tier from almost every other firm on this page. Founded by Ishay Davidi in 1996, the firm has completed 117 investments over nearly three decades, targeting Israeli companies and Israeli-related businesses with significant growth potential. The breadth of that portfolio, and the scale of capital deployed across it, means FIMI functions more like a national PE institution than a specialist fund.
For founders and sellers evaluating buyers, FIMI's check size and operational depth are relevant considerations. For co-investors or LPs mapping the Israeli market, it is the benchmark against which other platform funds are typically measured.
2. First Israel Mezzanine Investors Ltd
The name is somewhat misleading given how the firm has evolved. First Israel Mezzanine Investors was founded in 1996 and has completed 86 investments, with Calcalist reporting that its most recent fund raised $1.75 billion, its largest in firm history, and that it oversees more than $11 billion in assets under management across its investment vehicles. Those figures place it firmly in the upper bracket of Israeli private equity by asset scale.
Given the overlap in founding year, founder name (Ishay Davidi), and headline fund size with FIMI Opportunity Funds, these two entities appear to be closely related or part of the same broader platform. Researchers working through the directory tool above should treat their profiles as connected and read each firm's page carefully before drawing conclusions about separate mandates or strategies.
3. Fortissimo Capital
Fortissimo Capital has raised six funds since its founding in April 2004, growing from an $80 million debut vehicle to a fifth fund that closed at $650 million, with total capital raised now exceeding $2.7 billion. That trajectory, roughly doubling fund size across successive vintages, reflects sustained LP confidence in what is a focused mandate: technology and industrial companies in Israel, with investment tickets ranging from $10 to $50 million.
The firm occupies a distinct position in the market. It is not a seed or early-stage investor, and it is not trying to be. Its second fund raised $110 million in 2008, during a period when many managers were pulling back, which gives some indication of how the firm has approached market cycles. For technology or industrial businesses at the buyout or significant-minority stage, Fortissimo is one of the most logical first calls in the Israeli market.
4. Arkin Holdings
Arkin Holdings is Israel's largest private healthcare investor, with more than $1.5 billion deployed specifically in that sector. The firm was built by Mori Arkin, whose background in pharmaceuticals is central to understanding its trajectory: he founded Agis as the certified Israeli pharmaceutical importer, and the business was acquired in 2005 for more than $800 million. Arkin Holdings emerged from that outcome and has since concentrated its capital in healthcare with a level of domain specificity that distinguishes it from the generalist PE platforms.
A related entity, Arkin Capital, manages over $2 billion in AUM across venture capital, private equity, and hedge funds. Arkin Bio Ventures, a joint venture between Arkin Holdings (51%) and Phoenix Group (49%), has raised a second fund at $140 million, focusing on biotech and life sciences. For founders in pharmaceutical or biotech development, few Israeli investors bring both the capital scale and the operational heritage that Arkin does.
5. aMoon Fund
aMoon describes itself as Israel's largest HealthTech fund, with more than $1.3 billion in AUM and a closed fund in 2022 that reached $330 million. It was founded in 2017 by Dr. Yair Schindel and Marius Nacht and is headquartered in Ra'anana. The fund operates across both early and later stages, which gives it a longer runway with portfolio companies than a typical stage-specific fund would have.
What sets aMoon apart from Arkin, the other major healthcare name in this market, is orientation. Arkin's roots are in pharmaceutical distribution and traditional healthcare businesses. aMoon's identity, as the name "HealthTech" signals, sits closer to digital health, health data, and technology-enabled medical innovation. The two are not substitutes for each other from a founder's perspective; they represent meaningfully different theories of value creation within the same sector.
6. Israel Growth Partners (IGP)
Founded in 2014 by Moshe Lichtman and Haim Shani, IGP has built $800 million in AUM across three funds, investing exclusively in technology growth-stage companies from its base in Herzliya. The portfolio data on its own website is precise enough to be useful: 23 investments, with the largest single investment at $110 million, the smallest at $10 million, and the average entry check at $15 million. That range tells you a lot about the firm's posture, it writes meaningful checks for companies that are already generating real revenue, but it is not competing for the mega-deals that FIMI or Fortissimo handle at the upper end.
For technology founders at the growth stage who want a firm that is specifically structured around that moment in a company's life rather than a generalist fund that also does growth deals, IGP is one of the more purpose-built options available in Israel.
7. Cedar Fund
Cedar Fund has been backing Israeli founders since 1997, making it one of the older active venture-oriented firms on this list. It has offices in Herzliya and Waltham, Massachusetts, a dual presence that reflects the reality of Israeli technology companies, many of which are built to operate across Israeli R&D and US commercial markets from early on. The fund has made 113 investments, and its most recent vehicle reached $399 million in AUM.
Cedar's longevity means it has operated through multiple Israeli technology cycles, which carries both an advantage and a limitation. It has seen how Israeli companies scale internationally over decades. It is not, however, positioned as a pure private equity buyout fund in the conventional sense, and founders seeking growth equity or early VC should use the filter tool above to understand where Cedar sits relative to their stage.
8. Goldrock Capital
Goldrock Capital was established in 1999 by Daniel Goldman as a single-family office to manage his family's wealth, and it has since evolved into a firm focused on Israeli growth companies, with investment tickets in the $10 to $50 million range. It is based in Beit Shemesh, which is less common among Israeli investment firms, most of which cluster around Tel Aviv and Herzliya.
The family office origin matters for how founders should think about the relationship. Goldrock is not deploying LP capital on the same fund lifecycle pressures as a traditional closed-end PE fund, which can translate into longer holding periods, more flexibility on deal structure, and a different set of portfolio management incentives. For the right growth-stage Israeli company, that distinction can be as relevant as the check size.
9. Advantage SportsTech Fund
Launched in February 2018 by OurCrowd in collaboration with Berlin-based leAD Sports Accelerator Management GmbH, the Advantage SportsTech Fund is the most narrowly focused vehicle on this list. It targets early-stage sports technology companies, with an average initial check size of $1 to $2 million and a target entry point at Series A. The fund was launched with a $50 million target fund size and is headquartered in Jerusalem at Hebron Road 28, and PitchBook records 16 investments to its name.
This is not a firm that competes for the same deals as FIMI or Fortissimo. Its relevance is highly specific: companies at the intersection of sports, media, fan engagement, or athlete performance technology that are raising at Series A and want a strategic investor with a dual Israeli-European footprint. Within that narrow mandate, there is no close comparable in the Israeli market.
10. Elysium Management
Elysium Management was founded in 2017 and operates out of Israel with an investment ticket size of $1 to $5 million. The firm's publicly available information is limited, and the sourced data does not support specific claims about sector focus, AUM, or portfolio composition. What the ticket range does indicate is that Elysium operates at the smaller end of the private equity spectrum in Israel, occupying territory between venture capital and mid-market PE.
Founders raising smaller rounds or seeking a more accessible entry point into institutional capital may find it worth reviewing Elysium's profile directly for current mandate and focus.
Let's Recap
The firms above sit in distinct segments that don't really compete with each other, so read them by type, not as one ranking. At the large end, FIMI Opportunity Funds (and the related First Israel Mezzanine Investors) are the most established institutional PE presence in Israel, multi-decade track records and fund sizes in the billions. Fortissimo Capital is a similar generalist but with a sharper technology and industrial focus across six funds. Those are the reference points when Israeli PE comes up at the macro level.
The specialists split cleanly:
- Healthcare, two flavours: Arkin Holdings, pharma heritage and the dominant force in traditional healthcare and biotech, versus aMoon, built around health technology as a digital, data-driven category. Not interchangeable, the choice changes how you pitch and what post-investment support looks like.
- Tech growth: Israel Growth Partners, a dedicated mandate rather than a generalist fund that dabbles in growth.
- Structural outliers: Cedar Fund, a long-running, venture-oriented firm with cross-border infrastructure for companies building toward the US; Goldrock Capital, a family office whose timeline and incentives differ from a closed-end fund; Advantage SportsTech, narrowly scoped but genuinely differentiated for the right founder; and Elysium Management at the smaller-ticket end.
Start with check size and stage: raising $1 to $5 million in sports tech points to a completely different shortlist than raising $30 million in health tech. Then use the sector filter to separate healthcare from generalist from tech-only, and the individual profiles for structural fit (fund lifecycle, family office, cross-border presence).
In a market this concentrated, the mistake isn't drowning in options, it's overlooking the one specialist whose mandate actually matches yours. Private Equity List's API and MCP tools guard against that: query the full Israeli set by segment, stage, and cheque size and surface every real match, or hand the criteria to an AI assistant like Claude and let it separate the healthcare, tech, and generalist mandates for you before you start pitching.